Eli Lilly and Company (NYSE:LLY – Get Free Report) saw unusually large options trading activity on Friday. Traders bought 36,170 call options on the stock. This is an increase of 54% compared to the average daily volume of 23,493 call options.
Eli Lilly and Company Stock Up 4.4 %
Shares of NYSE:LLY opened at $565.22 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63. Eli Lilly and Company has a 52-week low of $309.20 and a 52-week high of $601.84. The stock’s fifty day simple moving average is $542.00 and its 200-day simple moving average is $461.44. The company has a market capitalization of $536.56 billion, a P/E ratio of 78.61, a P/E/G ratio of 2.19 and a beta of 0.33.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The business had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. During the same period in the prior year, the business earned $1.25 earnings per share. The business’s revenue was up 28.1% on a year-over-year basis. As a group, equities research analysts forecast that Eli Lilly and Company will post 9.84 earnings per share for the current fiscal year.
Analyst Ratings Changes
Insiders Place Their Bets
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 204,409 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $523.74, for a total transaction of $107,057,169.66. Following the completion of the transaction, the insider now directly owns 100,823,810 shares of the company’s stock, valued at $52,805,462,249.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CAO Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $546.51, for a total transaction of $327,906.00. Following the completion of the sale, the chief accounting officer now directly owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 204,409 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $523.74, for a total transaction of $107,057,169.66. Following the sale, the insider now directly owns 100,823,810 shares of the company’s stock, valued at $52,805,462,249.40. The disclosure for this sale can be found here. Insiders sold 693,246 shares of company stock valued at $20,948,820,977 over the last three months. 0.13% of the stock is owned by company insiders.
Hedge Funds Weigh In On Eli Lilly and Company
Several large investors have recently added to or reduced their stakes in LLY. Fairfield Bush & CO. purchased a new position in Eli Lilly and Company during the first quarter worth about $107,000. Roundview Capital LLC grew its stake in shares of Eli Lilly and Company by 2.6% in the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after buying an additional 53 shares in the last quarter. Merit Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at about $210,000. NewEdge Advisors LLC grew its stake in shares of Eli Lilly and Company by 9.9% in the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after buying an additional 4,774 shares in the last quarter. Finally, Barometer Capital Management Inc. acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at about $561,000. 81.38% of the stock is currently owned by hedge funds and other institutional investors.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- How to Capture the Benefits of Dividend Increases
- Levi Strauss: A Bottom is in for Steady, Stable Dividend Payer
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Starbucks Is About To Become A Value Play You Can’t Miss
- How to Invest in Canada for Beginners
- Intel to Unlock Value By Spinning Off Programmable Chip Unit
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
